PORT WASHINGTON, N.Y., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET - News), a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceuticals products, agricultural protection products and specialty chemicals today announced that Rising Pharmaceuticals Inc., its generic finished dosage form subsidiary, has launched the 250 mg and 500 mg strengths of Flucytosine(R) Capsules, the first approved generic version of Valeant Pharmaceuticals International’s Ancobon(R) Capsules, and 500 mg strength of Chloroquine Phosphate(R) Tablets, an approved generic version of Sanofi Aventis US’s Aralen(R) Tablets, following the U.S. Food and Drug Administration (FDA) approval of both Abbreviated New Drug Applications (ANDA’s). According to IMS Health data, U.S. brand sales for Flucytosine(R), which is used in the treatment of serious infections, and Chloroquine Phosphate(R), which is used to treat and prevent malaria infections, were approximately $20 Million collectively for the twelve months ended June, 2011.
